Exenatide for Weight Loss
Research, mechanism, dosing, and effectiveness of Exenatide for weight loss.
Quick Answer
Exenatide produces modest weight loss as a secondary benefit to diabetes treatment.
Evidence Level
FDA Approved
Typical Dose
10 mcg twice daily or 2 mg weekly
Results Timeline
Weight loss over 3-6 months
FDA Status
FDA Approved
How Exenatide Works for Weight Loss
GLP-1 activation reduces appetite and slows gastric emptying.
About Weight Loss
Reduction of body fat and overall body weight through appetite control and metabolic enhancement.
Research Evidence
First-in-class GLP-1 agonist with extensive clinical experience since 2005. Studies show 2-4% weight loss and A1C reductions of 0.5-1%. Weekly formulation (Bydureon) provides more consistent levels.
Dosing for Weight Loss
Recommended Dose
10 mcg twice daily or 2 mg weekly
Frequency
Twice daily (IR) or once weekly (ER)
Administration
Subcutaneous injection
Duration
Long-term / chronic use
Note: First GLP-1 approved. Byetta (twice daily) or Bydureon (weekly). Must be injected.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (common)
- •Vomiting
- •Diarrhea
- •Dizziness
- •Hypoglycemia
- •Injection site reactions
Frequently Asked Questions
Does Exenatide help with weight loss?
Exenatide produces modest weight loss as a secondary benefit to diabetes treatment.
How does Exenatide work for weight loss?
GLP-1 activation reduces appetite and slows gastric emptying....
What dose of Exenatide should I use for weight loss?
10 mcg twice daily or 2 mg weekly
How long until I see results?
Weight loss over 3-6 months
Other Peptides for Weight Loss
These peptides are also researched for weight loss.
Semaglutide
FDAA GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Tirzepatide
FDAA dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.
Liraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Dulaglutide
FDAAn FDA-approved weekly GLP-1 receptor agonist for type 2 diabetes. Fused to an Fc antibody fragment for extended duration of action.
Educational Information Only
This information about Exenatide for weight loss is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.